VZL 2007, 76(6):205-210

Predictive and Prognostic Factors of Invasive Breast Cancer in Practice

Petr Cinek1, Stanislav Filip2
1 Oddělení klinické onkologie Ústřední vojenské nemocnice Praha, Praha
2 Klinika onkologie a radioterapie Fakultní nemocnice a Lékařské fakulty Univerzity Karlovy, Hradec Králové

Invazivní karcinom prsu je nemoc heterogenní. Nejenže pacientky přicházejí v různých stadiích vývoje onemocnění, ale tumory jsou také velmi odlišné, pokud jde o rychlost jejich růstu, schopnost metastazovat a další biologické vlastnosti. Pro karcinom prsu byla stanovena celá řada důležitých prognostických a preditivních faktorů. Těmi hlavními jsou klinické stadium onemocnění, velikost primárního nádoru, stav spádových lymfatických uzlin, histologický typ karcinomu, stupeň diferenciace (grading), stav exprese steroidních receptorů a receptoru HER-2/neu, invaze do krevních a lymfatických cév, markery proliferační aktivity, biologický a hormonální věk pacientky, hodnoty sérových markerů. V naší práci jsme vyhodnotili soubor pacientek s invazivním karcinomem prsu léčených na Oddělení klinické onkologie ÚVN Praha v letech 1991-2004 se zaměřením na prognostický význam těchto ukazatelů: velikost primárního nádoru, patologická N-klasifikace, stadium onemocnění, grading, stav exprese estrogenových receptorů (ER), stav exprese receptoru HER-2/neu a typ provedené operace.

Keywords: Invazivní karcinom prsu; Prognostický faktor; Prediktivní faktor; Celkové přežití

The invasive breast cancer is a heterogenous disease. Patients come not only with different stages of the disease, but also their carcinomas are various in growth speed, metastatic potency and other biological attributes. A number of important prognostic and predictive factors was determined for breast cancer. The main factors are clinical stage, size of primary tumor, involvement of regional lymph nodes, histological type of carcinoma, grade, status of steroid and HER-2/neu receptors expression, invasion into blood and lymph vessels, proliferative markers, biological and hormonal age of patients, and levels of serum markers. In our study we evaluated a group of breast cancer patients who were treated at the Department of Clinical Oncology of the Central Military Hospital Prague in 1991-2004, with a view to prognostic signification of these indicators: primary tumor size, pathological N classification, stage, grade, oestrogen receptor (ER) expression, HER-2/neu receptor status and type of performed surgery.

Keywords: Invasive breast cancer; Prognostic factor; Predictive factor; Overall survival

Received: March 9, 2007; Published: December 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cinek, P., & Filip, S. (2007). Predictive and Prognostic Factors of Invasive Breast Cancer in Practice. Vojenské Zdravotnické Listy, 76(6), 205-210
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. CIANFROCCA, M. - GOLDSTEIN, LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist., 2004, vol. 9, no. 6, p. 606-616. Go to original source... Go to PubMed...
    2. DILLON, DA. Molecular Markers in the Diagnosis and Staging of Breast Cancer. Seminars in Radiation Oncology, 2002, vol. 12, no. 4, p. 305-318. Go to original source... Go to PubMed...
    3. DOWSETT, M., et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol., 2003, vol. 199, no. 4, p. 411-417. Go to original source... Go to PubMed...
    4. FALO, C., et al. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas. Am. J. Clin. Oncol., 2003, vol. 26, no. 5, p. 465-470. Go to original source... Go to PubMed...
    5. KENDAL, WS. Lymph node-based prognostics: limitations with individualized cancer treatment. Am. J. Clin. Oncol., 2006, vol. 29, no. 3, p. 298-304. Go to original source... Go to PubMed...
    6. KLENER, P. Klinická onkologie. 2002.
    7. LESAR, M. - STANEC, M. - BANOVIC M. Significance of the relative size of a breast tumor in deciding the method of surgical treatment. Tumori, 2006, vol. 92, no. 1, p. 18-20. Go to original source... Go to PubMed...
    8. MÉNARD, S., et al. Biologic and therapeutic role of HER2 in cancer. Oncogene, 2003, vol. 22, no. 42, p. 6570-6578. Go to original source... Go to PubMed...
    9. OGURA, H., et al. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry. Breast Cancer, 2003, vol. 10, no. 3, p. 234-240. Go to original source... Go to PubMed...
    10. PONZONE, R., et al. Antihormones in prevention and treatment of breast cancer. Ann. N. Y. Acad. Sci., 2006, 1089, p. 143-158. Go to original source... Go to PubMed...
    11. TAGLIABUE, E., et al. The early relapse of premenopausal patients after surgery for node-positive breast carcinoma. Breast Cancer Re.s Treat., 2001, vol. 70, no. 2, p. 155-156.
    12. XU, R., et al. Amplification of HER-2/neu Gene in HER-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material. Modern Pathology, 2002, vol. 15, no. 2, p. 116-124. Go to original source... Go to PubMed...

    Return to the content